Pirfenidone Market
The market for Pirfenidone was estimated at $956 million in 2024; it is anticipated to increase to $1.42 billion by 2030, with projections indicating growth to around $1.97 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Pirfenidone Market Outlook
Revenue, 2024
$956M
Forecast, 2034
$1.85B
CAGR, 2025 - 2034
6.8%
The Pirfenidone industry revenue is expected to be around $1020.9 million in 2025 and expected to showcase growth with 6.8% CAGR between 2025 and 2034. The rising need for Pirfenidone is mainly driven by a rise in the occurrence of pulmonary fibrosis (IP) and an increasing awareness among patients about new and advanced treatment options available in the market today. The drug’s ability to slow down the advancement of IP has positioned it as a leading player in the pharmaceutical industry, at present. The consistent growth of the market indicates the continued importance and significant impact that Pirfenidone holds in the healthcare field. Factors such as changes in population demographics and advancements in treating IPFs and better access, to healthcare all contribute to the continued importance of the market.
Pirfenidone serves as a medication by effectively controlling and suppressing the generation of growth factors and cytokines that trigger fibrosis development in the body. This unique capability has positioned Pirfenidone as a component in treating various fibrotic conditions like idiopathic pulmonary fibrosis. Moreover recent developments in healthcare practices like personalized treatment approaches and improvements in techniques have notably increased the need for Pirfenidone, in medical practices.
Market Key Insights
- The Pirfenidone market is projected to grow from $955.9 million in 2024 to $1.85 billion in 2034. This represents a CAGR of 6.8%, reflecting rising demand across Idiopathic Pulmonary Fibrosis Treatment, Anti-fibrotic Therapy and Nephropathy Treatment.
- Roche Holding AG, Shionogi & Co. Ltd., Cipla Ltd. are among the leading players in this market, shaping its competitive landscape.
- U.S. and China are the top markets within the Pirfenidone market and are expected to observe the growth CAGR of 4.4% to 6.5% between 2024 and 2030.
- Emerging markets including Brazil, South Korea and Mexico are expected to observe highest growth with CAGR ranging between 7.8% to 9.4%.
- Transition like Pirfenidone and Evolving Medical Prescription Patterns has greater influence in United States and China market's value chain; and is expected to add $49 million of additional value to Pirfenidone industry revenue by 2030.
- The Pirfenidone market is set to add $890 million between 2024 and 2034, with manufacturer targeting Kidney Diseases & Nervous System Disorders Application projected to gain a larger market share.
- With The increasing prevalence of idiopathic pulmonary fibrosis , and Technological advancements in drug delivery systems, Pirfenidone market to expand 93% between 2024 and 2034.
Opportunities in the Pirfenidone
In the realm of biotechnology progressions lie the possibilities of creating modes of delivering Pirfenidone that can also enhance its effectiveness while reducing adverse reactions significantly.
Growth Opportunities in North America and Europe
In North America's market for Pirfenidone is on the rise due to developments in lung treatments and a high occurrence of Pulmonary Fibrosis along with a strong healthcare system network in place. With companies like Genentech dominating the market with products such as Esbriet and facing significant competition. Additionally the regulatory framework supports trials and expedites approval procedures making for a conducive environment, for Pirfenidones expansion. The rise of medication trends plays a crucial role in driving the use of Pirfenidone, for treating IPV in this region and contributing to market growth.
In Europe's Pirfenidone market is examined considering the medical facilities and a growing population of elderly individuals at risk of respiratory issues. As the market benefits are derived through increased partnerships between pharmaceutical companies such as Roche and local government bodies, for the delivery and availability of IPD treatment. Increased healthcare spending introduction of drug generation and a heightened awareness of IPD are key factors driving growth in the European Pirfenidone market. Nevertheless there is competition due to the popularity of drugs such as Nintedaniel, which highlights the need for continuous exploration and creativity, in advancing Pirfenidone.
Market Dynamics and Supply Chain
01
Driver: The Increasing Prevalence of Idiopathic Pulmonary Fibrosis, and Strong Clinical Pipeline and Research Efforts
The rising number of cases of IPFs around the world plays a role in driving the expansion of the Pirfenidone market sector significantly. As a therapy for IPFs Pirfenidones popularity is also directly correlated with the growing incidence of this severe ailment. This essential medication helps to slow down the advancement of IPFs by lessening the deterioration in lung function and improving patients’ lifespan resultantly resulted in an upsurge, in its necessity. The promising future for Pirfenidone lies in research endeavors and a robust clinical pipeline dedicated to creating improved and safer versions of the medication. Exploring therapeutic uses for Pirfenidone could also pave the way, for lucrative opportunities and further market growth.
The advancement of drug delivery methods has also significantly contributed to the growth of the Pirfenidone market. The development of drug delivery techniques aims to increase the absorption of drugs in the body while also enhancing their therapeutic benefits and minimizing adverse reactions. In light of Pirfenidones significance in treating IPF advancements in technology, within this field are also anticipated to enhance patient results and adherence levels—ultimately propelling market expansion.
02
Restraint: High Pricing Structure
Pirfenidone is known for its effectiveness in treating pulmonary fibrosis but its high cost poses a challenge to widespread adoption and accessibility of the treatment option for patients, across different income levels and regions worldwide. The interplay of these elements puts pressure on the demand trends. Contributes to a delayed adoption of Pirfenidone despite its increasing acknowledgment, within the medical field.
03
Opportunity: Strategic Collaborations Fostering Growth and Exploiting Untapped Therapeutic Sectors
Pharmaceutical firms stand to gain advantages by forming alliances to broaden their impact in the industry space. These partnerships with institutions or fellow pharmaceutical entities could accelerate the process of exploring fresh possibilities for Pirfenidone, through research and development efforts and bring new products to market more swiftly. Ultimately driving substantial growth in the market sector.
Pirfenidone has been identified as a treatment for pulmonary fibrosis and is known to have anti inflammatory and antioxidant effects as well. This makes it suitable for use in addressing inflammatory and fibrotic conditions beyond its primary indication. The unexplored potential in this area presents promising avenues, for the growth of pirfenidone.
04
Challenge: Stringent Regulatory Hurdle
Stringent regulatory requirements significantly influence the market growth of Pirfenidone due to the need for clinical trials and quality assessments before receiving approval in specific markets. For example despite gaining approval, in Europe in 2011 it faced a delay of three years before being accepted in the U. S.
Supply Chain Landscape
1
Raw Material Procurement
Biogenic Stimulants IncAlpha Aesar
2
API Production
RocheCipla
3
Formulation & Packaging
Nichi-Iko Pharmaceutical Co LtdShandong New Time Pharmaceutical
4
Distribution & Retail
Sun Pharmaceutical IndustriesZhejiang Hisun Pharmaceutical
1
Raw Material Procurement
Biogenic Stimulants IncAlpha Aesar
2
API Production
RocheCipla
3
Formulation & Packaging
Nichi-Iko Pharmaceutical Co LtdShandong New Time Pharmaceutical
4
Distribution & Retail
Sun Pharmaceutical IndustriesZhejiang Hisun Pharmaceutical
Use Cases of Pirfenidone in Idiopathic Pulmonary Fibrosis Treatment & Anti-fibrotic Therapy
Idiopathic Pulmonary Fibrosis Treatment : Primarily used to treat pulmonary fibrosis Pirfenidone showcases its anti fibrotic properties to slow down the advancement of fibrosis in patients with this condition. As a player in this field Roche stands out with its product Esbriet that proves effective in the treatment of IPD. This treatment offers benefits such as slowing down disease progression and improving lung function and ultimately enhancing life expectancy for individuals, with IPD.
Nephropathy Treatment : Pirfenidone is widely used to treat kidney disease like nephropathy and is mostly consumed orally to prevent kidney scarring effectively in this context. With a presence in the market for treating kidney disease conditions like nephropathy Shionogi & Co. Ltd offers a popular Pirfenidone medication that is known for effectively reducing kidney damage in individuals, with diabetes. One key benefit of Pirfenidone is its ability to slow down the progression of disease and enhance the overall health of the kidneys.
Anti-fibrotic Therapy : Pirfenidone is commonly utilized as a fibrotic treatment for conditions, like liver cirrhosis and scleroderma to combat fibrosis and inflammation effectively.
Recent Developments
Pirfenidone has seen progress in its usage as a medication for treating idiopathic pulmonary fibrosis . The global expansion of Pirfenidone has been driven by adjustments, in the pharmaceutical industry to cater to increasing market needs.
December 2024 : Pfizer unveiled a marked improvement in the production process for Pirfenidone, sharply increasing overall output while simultaneously reducing costs.
October 2024 : Novartis created a finely powdered version of Pirfenidone expanding its presence, in the field of idiopathic pulmonary fibrosis .
June 2024 : Roches groundbreaking research with Pirfenidone showcased effectiveness in decelerating the decrease in lung function among individuals with systemic sclerosis. This discovery has paved the way for an approach to treatment, in this field.
Impact of Industry Transitions on the Pirfenidone Market
As a core segment of the Pharmaceutical industry,
the Pirfenidone market develops in line with broader industry shifts.
Over recent years, transitions such as Pirfenidone and Evolving Medical Prescription Patterns and The Growth of Generic Pirfenidone have redefined priorities
across the Pharmaceutical sector,
influencing how the Pirfenidone market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Pirfenidone and Evolving Medical Prescription Patterns
With the growing acknowledgement of the anti scarring properties of Pirfenidone in the medical field there has been a noticeable shift in how doctors prescribe medications. In the past corticosteroids were commonly used to treat scarring conditions like pulmonary fibrosis but Pirfenidones effectiveness and tolerability have made it a preferred choice now. As a result it is increasingly being adopted as the treatment in respiratory medicine departments worldwide marking a significant change in frontline defenses, against IPFE. The ripple effect has extended to industries as well encouraging pharmaceutical firms to allocate substantial resources toward Pirfenidone exploration thereby igniting progress, in medication advancement.
02
The Growth of Generic Pirfenidone
The Pirfenidone market is shifting as generic versions of the medication are being introduced into the market.